[{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Receives the EMA PRIME Designation for Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"T lymphocyte","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Medicines Agency Grants Orphan Drug Designation to AlloVir\u2019s Viralym-M","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Viralym-M","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"AlloVir","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AlloVir, Baylor ally to develop COVID-19 T-cell therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Collaboration","leadProduct":"ALVR106","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ AlloVir","highestDevelopmentStatusID":"4","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"The Invus Group","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Closes $170 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","year":"2020","type":"Series B Financing","leadProduct":"Cell and gene therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0.17000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"ElevateBio \/ The Invus Group","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"BlackRock","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Annexon, AlloVir Gun for $100M IPOs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0.10000000000000001,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AlloVir \/ BlackRock","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","amount":"$276.2 million","upfrontCash":"Undisclosed","newsHeadline":"Allovir Raises $276M IPO to Run Broad Cell Therapy Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Public Offering","leadProduct":"ALVR105","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0.28000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces the FDA Clearance of Investigational New Drug Application for ALVR109 for the Treatment of High-Risk COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"ALVR109","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TCR\u00b2 Therapeutics Announces Partnership with Elevatebio to Expand TC-210 Manufacturing Capacity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Partnership","leadProduct":"TC-210","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ TCR\u00b2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation (ODD) to AlloVir\u2019s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir\u2019s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Kelonia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kelonia Therapeutics Launches with $50 Million Series A Financing to Pioneer Precision Targeted Genetic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"LVV-based GeneTherapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"$126.6 million","upfrontCash":"Undisclosed","newsHeadline":"AlloVir Announces $126.6 Million Registered Direct Offering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.13,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Kite","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Children\u2019s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"iPSC-derived Allogeneic Immune Therapies","moa":"CD19","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Partnership","leadProduct":"iPSC-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T's T Cell Therapy Programs Targeting Core Oncogenic Drivers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Partnership","leadProduct":"TCR-engineered T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"4","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","amount":"$401.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Series D Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0.40000000000000002,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"ElevateBio \/ AyurMaya Capital Management Fund","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio.."},{"orgOrder":0,"company":"AlloVir","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"AlloVir Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Public Offering","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.01,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"AlloVir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Posoleucel","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ .."},{"orgOrder":0,"company":"ElevateBio","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xcell Biosciences Announces Collaboration with ElevateBio to Advance Technology Development for Cell and Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio.."}]

Find Clinical Drug Pipeline Developments & Deals by ElevateBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The collaboration aims to explore novel approaches to improving therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR™ incubator system for cell therapy research and developme...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 11, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Recipient : Xcell Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : ALVR105 (posoleucel) is a T-lymphocyte cell therapy which is under phase 3 clinical development for the treatment of adenovirus infections, BK virus infections & Epstein-Barr virus infection.

                          Product Name : ALVR105

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          December 22, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The company intends to use the net proceeds to complete enrollment and achieve data readouts in all three of its ongoing Phase 3 trials of its lead multi-virus specific candidate, Viralym-M (posoleucel), ...

                          Product Name : Viralym-M

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 21, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : J.P. Morgan

                          Deal Size : $7.5 million

                          Deal Type : Public Offering

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Partner/Sponsor/Collaborator : AyurMaya Capital Management Fund

                          Deal Size : $401.0 million

                          Deal Type : Series D Financing

                          Details : The proceeds will advance the company’s technology platforms, Life Edit gene editing, iPSCs, and RNA, cell, protein, vector engineering and BaseCamp®, to accelerate the design, manufacturing, and devel...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 24, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Partner/Sponsor/Collaborator : AyurMaya Capital Management Fund

                          Deal Size : $401.0 million

                          Deal Type : Series D Financing

                          blank

                          05

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging imm...

                          Product Name : Viralym-M

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          February 15, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging imm...

                          Product Name : Viralym-M

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          January 09, 2023

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Affini-T will leverage ElevateBio BaseCamp’s LentiPeak™ lentiviral vector technology platform and cell therapy production capabilities to advance its investigational oncogenic driver programs into cli...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 15, 2022

                          Lead Product(s) : TCR-engineered T Cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Affini-T Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          08

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : iPSC-based Therapeutic

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Partner/Sponsor/Collaborator : California Institute for Regenerative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : The partnership with CIRM reflects the novelty of the iPSC platform and recognition of next-generation cell lines that address industry challenges and could potentially save time and costs for partners de...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 23, 2022

                          Lead Product(s) : iPSC-based Therapeutic

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Partner/Sponsor/Collaborator : California Institute for Regenerative Medicine

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : iPSC-derived Allogeneic Immune Therapies

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Peer-reviewed publication in Cell Stem Cell unveils a novel differentiation process from develop mature immune cells from induced pluripotent stem cells (iPSCs), a potentially disruptive advantage in the ...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          August 04, 2022

                          Lead Product(s) : iPSC-derived Allogeneic Immune Therapies

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : AlloVir intends to use the net proceeds from the offering, to complete enrollment and achieve data readouts in all three of the Company’s ongoing Phase 3 trials of its lead multi-virus specific T-cell t...

                          Product Name : Viralym-M

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 27, 2022

                          Lead Product(s) : Posoleucel

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Partner/Sponsor/Collaborator : Kite Pharma

                          Deal Size : $126.6 million

                          Deal Type : Public Offering

                          blank